What is LEDIPASVIR & SOFOSBUVIR 90/400 MG LEDIFOS?
LEDIPASVIR and SOFOSBUVIR 90/400 MG LEDIFOS Tablet is a blend of two antiviral meds. This doctor-prescribed medication is utilized in the therapy of constant hepatitis C infection (HCV) disease. It battles against the infections to determine the disease.
How is Used LEDIPASVIR & SOFOSBUVIR 90/400 MG LEDIFOS?
Ledifos 90mg/400mg Tablet ought to be taken in the endorsed portion and span. It very well may be taken with or without food, yet take it simultaneously day by day. It is exhorted not to burn through more than the suggested portion. It is critical to advise your primary care physician if you have any medical issues like liver or kidney illness. It is destructive to devour liquor alongside this medication, so it is encouraged to restrict or stay away from liquor. The course of the medication ought to be finished for better outcomes.
It works by diminishing the measure of hepatitis C infection (HCV) in the body. Ledipasvir is in a class of antiviral prescriptions called HCV NS5A inhibitors. It works by halting the infection that causes hepatitis C from spreading inside the body.
What sort of medication is Sofosbuvir?
Sofosbuvir is in a class of antiviral prescriptions called nucleotide hepatitis C infection (HCV) NS5B polymerase inhibitors. Velpatasvir is in a class of antiviral prescriptions called HCV NS5A replication complex inhibitors.
Side effects of LEDIPASVIR & SOFOSBUVIR 90/400 MG LEDIFOS:
The regular results of this medication are sleepiness and migraine. You should drink a lot of liquid and eat a solid eating routine to forestall or beat the results. Before taking the medication, educate your primary care physician if you are taking some other drugs or enhancements. For more details click here.
Business trademark:- LEDIFOS
Producer: HETERO
Show: Tablet
Strength: 400mg
We are exporting medicines from India to different countries like United Arab Emirates, United States, Brazil, Saudi Arabia, etc. If you are looking for another product or brand click here.
